PLM-102 for leukemia that has come back or not responded
Part of Blood & lymphatic, Cancer clinical trials.
This phase 1 trial tests a new drug called PLM-102 for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard treatment. The goal is to find the best dose and see if it can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with acute myeloid leukemia (AML) or a related bone marrow disease that has come back or hasn't responded to standard treatment.
- You must be able to do most daily tasks yourself (ECOG performance status 0-2).
- Your liver and kidneys must be working well enough (liver tests within limits, creatinine clearance at least 45 mL/min).
- If you've had a stem cell transplant, you must be off immune-suppressing drugs for at least 2 weeks.
- You must agree to use effective birth control during the study and for at least 3 months after treatment (if you or your partner can become pregnant).
- Your white blood cell count must be manageable; if it's too high, you can receive medication to lower it before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.